Dyno Therapeutics, Inc.
Industry
- Biotechnology
- Drug Discovery Technologies
- Bioinformatics
- Gene Therapy, Cell Therapy
- Drug Discovery Technologies
- Pharmaceuticals
- Digital Health
- Artificial Intelligence
Latest on Dyno Therapeutics, Inc.
Artificial intelligence was more than a buzzword in 2024; it shaped pharmaceutical industry investments throughout the year, with multiple billion-dollar partnerships and acquisitions across the drug
BioBytes presents an overview of select AI-focused M&As, partnerships and financings in the biopharma industry in Q4 2024. Of note are a $1.05bn partnership between Roche and Dyno Therapeutics and
AstraZeneca is to spend around $68m to acquire the beleaguered LogicBio Therapeutics and its gene therapy platform – a generous payout which could provide a template for further deals in the space.
Who: Roche Holding AG and Avista Therapeutics What: The two companies signed a partnership to use Avista’s intravitreal AAV platform technology to develop AAV capsids matching a profile defined by